Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Holders of 5% or more of ADAPY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Adaptimmune Therapeutics PLC, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Long Focus Capital Management, LLC | 13G/A | 8.00%20.5M shares | – | Feb 11, 20251 filing | Feb 11, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Adaptimmune Therapeutics PLC, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 202511:42 AM ET | Two Seas Capital LPand 2 others | 13G/A | 0.00%0 shares | −8.50 ppfrom 8.50%Below 5% | Sep 30, 2025 | SEC |
| Aug 19, 20256:53 PM ET | New Enterprise Associates 14, L.P.and 10 others | 13D/A | 0.00%4 shares | –Below 5% | Aug 15, 2025 | SEC |
| Aug 19, 20256:32 PM ET | EcoR1 Capital, LLCand 2 others | 13G/A | 4.20%66.0M shares | –Below 5% | Aug 15, 2025 | SEC |
| Aug 13, 20255:43 PM ET | Two Seas Capital LPand 2 others | 13G/A | 8.50%135.5M shares | +0.50 ppfrom 8.00% | Jun 30, 2025 | SEC |
| May 15, 20259:00 AM ET | Two Seas Capital LPand 2 others | 13G/A | 8.00%123.2M shares | +2.20 ppfrom 5.80% | Mar 31, 2025 | SEC |
| Feb 14, 20259:31 AM ET | Two Seas Capital LPand 2 others | 13G | 5.80%89.0M shares | New | Dec 31, 2024 | SEC |
| Feb 12, 202510:25 AM ET | Baillie Gifford & Co | 13G/A | 4.60%70.9M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 11, 20254:40 PM ET | Long Focus Capital Management, LLCand 4 others | 13G/A | 8.00%20.5M shares | – | Dec 31, 2024 | SEC |
| Jan 8, 202510:30 AM ET | Matrix Capital Management Company, LPand 1 other | 13G/A | 0.00%0 shares | −8.80 ppfrom 8.80%Below 5% | Dec 31, 2024 | SEC |
| Dec 5, 20245:17 PM ET | Matrix Capital Management Company, LPand 1 other | 13G/A | 8.80%135.0M shares | – | Nov 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Adaptimmune Therapeutics PLC shares.
No Form 144 notices for Adaptimmune Therapeutics PLC are on file.